Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity

Canadian Journal of Physiology and Pharmacology

Volumn 85, Issue 2, 2007, Pages 233-242

  Ouazzani Chahdi, Amine ^a   Elimadi, Aziz ^a   Chabli, Allal ^a   Spénard, Jean ^a,b   Colin, Patrick ^b   Haddad, Pierre S ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Axcan Pharma Inc   (Canada)

Author keywords

Apoptosis; NASH; NCX 1000; Necrosis; Oxidative stress; Primary hepatocytes; UDCA

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANTIOXIDANT; ASCORBIC ACID; BUTYLCRESOL; CRESOL; MALONALDEHYDE; NCX 1000; NITRIC OXIDE DONOR; SUPEROXIDE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HYDROPHILICITY; INCUBATION TIME; LD 50; LIPID PEROXIDATION; LIPOPHILICITY; LIVER CELL CULTURE; NECROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL;

AMIODARONE; ANIMALS; ANTIOXIDANTS; ASCORBIC ACID; BUTYLATED HYDROXYTOLUENE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY LIVER; HEPATOCYTES; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED BALB C; NITRATES; PROTECTIVE AGENTS; SUPEROXIDES; URSODEOXYCHOLIC ACID;

EID: 34249783134     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y07-015     Document Type: Article

References (25)

1. Albano, E., Mottaran, E., Occhino, G., Reale, E., and Vidali, M. 2005. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment. Pharmacol. Ther. 22: 71-73. doi:10.1111/j.1365-2036. 2005.02601.x.
2. Berson, A., De Beco, V., Letteron, P., Robin, M.A., Moreau, C., El Kahwaji, J., et al. 1998. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology, 114: 764-774. doi:10.1016/S0016-5085(98)70590-6.
3. Botla, R., Spivey, J.R., Aguilar, H., Bronk, S.F., and Gores, G.J. 1995. Ursodeoxycholate (UDCA) inhibits the mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA cytoprotection. J. Pharmacol. Exp. Ther. 272: 930-938.
4. Brigelius-Flohe, R., and Traber, M.G. 1999. Vitamin E: function and metabolism. FASEB J. 13: 1145-1155.
5. Chitturi, S., and Farrell, G.C. 2000. Drug-induced liver disease. Curr. Treat. Options Gastroenterol. 3: 457-462.
6. Chow, C.K. 2001. Vitamin E regulation of mitochondrial superoxide generation. Biol. Signals Recept. 10: 112-124. doi:10.1159/000046879.
7. Day, C.P. 2002. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut, 50: 585-588.
8. Day, C.P., and James, O.F. 1998. Steatohepatitis: a tale of two hits? Gastroenterology, 114: 842-845. doi:10.1016/S0016-5085(98)70599-2.
9. Fiorucci, S., Mencarelli, A., Palazzetti, B., Del Soldata, P., Morelli, A., and Ignarro, L.J. 2001. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc. Natl. Acad. Sci. U.S.A. 98: 2652-2657. doi:10.1073/pnas.041603898.
10. Fromenty, B., Fisch, C., Berson, A., Letteron, P., Larrey, D., and Pessayre, D. 1990. Dual effect of amiodarone on mitochondrial respiration: Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J. Pharmacol. Exp. Ther. 255: 1377-1384.
11. Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I., and Terano, A. 2001. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment. Pharmacol. Ther. 15: 1667-1672. doi:10.1046/j.1365-2036.2001.01083.x.
12. James, O.F., and Day, C.P. 1998. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J. Hepatol. 29: 495-501. doi:10.1016/S0168-8278(98)80073-1.
13. Joshi, S., Cauch-Dudek, K., Wanless, I.R., Lindor, K.D., Jorgensen, R., Batts, K., and Heathcote, E.J. 2002. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology, 35: 409-413. doi:10.1053/jhep.2002.30902.
14. Kim, J.S., Ohshima, S., Pediaditakis, P., and Lemasters, J.J. 2004. Nitric oxide protects rat hepatocytes against reperfusion injury mediated by the mitochondrial permeability transition. Hepatology, 39: 1533-1543. doi:10.1002/hep.20197.
15. Laurin, J., Lindor, K.D., Crippin, J.S., Gossard, A., Gores, G.I., Ludwig, J., et al. 1996. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology, 23: 1464-1467. doi:10.1002/hep.510230624.
16. Lavine, J.E. 2000. Vitamin E treatment on nonalcoholic steatohepatitis in children: a pilot study. J. Pediatr. 136: 734-738. doi:10.1067/mpd.2000. 106566.
17. Lindor, K.D., Kowdley, K.V., Heathcote, E.J., Harrison, M.E., Jorgensen, R., Angulo, P., et al. 2004. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology, 39: 770-778. doi:10.1002/hep.20092.
18. Ludwig, J., Viggiano, T.R., and McGill, D.B. 1980. Nonalcoholic steatohepatitis. Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin. Proc. 55: 434-438.
19. Oliveira, C.P., Gayotto, L.C., Tatai, C., Della Bina, B.I., Janiszewski, M., Lima, E.S., et al. 2002. Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J. Cell. Mol. Med. 6: 399-406.
20. Palmeira, C.M., and Rolo, A.P. 2004. Mitochondrially-mediated toxicity of bile acids. Toxicology, 203: 1-15. doi:10.1016/j.tox.2004.06.001.
21. Pessayre, D., Berson, A., Fromenty, B., and Mansouri, A. 2001. Mitochondria in steatohepatitis. Semin. Liver Dis. 21: 57-69. doi:10.1055/s-2001-12929.
22. Ruch, R.J., Bandyopadhyay, S., Somani, P., and Klaunig, J.E. 1991. Evaluation of amiodarone free radical toxicity in rat hepatocytes. Toxicol. Lett. 56: 117-126. doi:10.1016/0378-4274(91)90097-P.
23. Sorrell, M.F., and Mukherjee, S. 1999. Non-alcoholic steatohepatitis (NASH). Curr. Treat. Options Gastroenterol. 2: 447-450.
24. Stiehl, A., Benz, C., and Sauer, P. 1999. Mechanism of hepatoprotective action of bile salts in liver disease. Gastroenterol. Clin. North Am. 28: 195-209. doi:10.1016/S0889-8553(05)70050-9.
25. Younossi, Z.M., Diehl, A.M., and Ong, J.P. 2002. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology, 35: 746-752. doi:10.1053/jhep.2002.32483.